IGM Biosciences Competitors

BridgeBio Pharma (NASDAQ:BBIO) and IGM Biosciences (NASDAQ:IGMS) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, institutional ownership, valuation, earnings and analyst recommendations.

Insider & Institutional Ownership

95.5% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 47.6% of IGM Biosciences shares are held by institutional investors. 40.3% of BridgeBio Pharma shares are held by company insiders. Comparatively, 79.3% of IGM Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for BridgeBio Pharma and IGM Biosciences, as reported by MarketBeat.

BridgeBio Pharma currently has a consensus target price of $72.8889, indicating a potential upside of 33.77%. IGM Biosciences has a consensus target price of $98.8750, indicating a potential upside of 44.36%. Given IGM Biosciences' higher probable upside, analysts plainly believe IGM Biosciences is more favorable than BridgeBio Pharma.

Valuation & Earnings

This table compares BridgeBio Pharma and IGM Biosciences' top-line revenue, earnings per share (EPS) and valuation.

IGM Biosciences has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BridgeBio Pharma and IGM Biosciences' net margins, return on equity and return on assets.

Risk and Volatility

BridgeBio Pharma has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of -1.12, meaning that its share price is 212% less volatile than the S&P 500.

Summary

BridgeBio Pharma beats IGM Biosciences on 7 of the 12 factors compared between the two stocks.

Ultragenyx Pharmaceutical (NASDAQ:RARE) and IGM Biosciences (NASDAQ:IGMS) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, institutional ownership, valuation, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of current recommendations for Ultragenyx Pharmaceutical and IGM Biosciences, as reported by MarketBeat.

Ultragenyx Pharmaceutical currently has a consensus target price of $131.20, indicating a potential upside of 26.79%. IGM Biosciences has a consensus target price of $98.8750, indicating a potential upside of 44.36%. Given IGM Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe IGM Biosciences is more favorable than Ultragenyx Pharmaceutical.

Risk and Volatility

Ultragenyx Pharmaceutical has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of -1.12, meaning that its share price is 212% less volatile than the S&P 500.

Insider & Institutional Ownership

47.6% of IGM Biosciences shares are held by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 79.3% of IGM Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Ultragenyx Pharmaceutical and IGM Biosciences' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Ultragenyx Pharmaceutical and IGM Biosciences' top-line revenue, earnings per share (EPS) and valuation.

IGM Biosciences has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. IGM Biosciences is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Summary

IGM Biosciences beats Ultragenyx Pharmaceutical on 8 of the 13 factors compared between the two stocks.

IGM Biosciences (NASDAQ:IGMS) and GW Pharmaceuticals (NASDAQ:GWPH) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Analyst Recommendations

This is a summary of recent recommendations and price targets for IGM Biosciences and GW Pharmaceuticals, as provided by MarketBeat.com.

IGM Biosciences currently has a consensus price target of $98.8750, indicating a potential upside of 44.36%. GW Pharmaceuticals has a consensus price target of $204.0909, indicating a potential downside of 6.35%. Given IGM Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe IGM Biosciences is more favorable than GW Pharmaceuticals.

Volatility & Risk

IGM Biosciences has a beta of -1.12, indicating that its stock price is 212% less volatile than the S&P 500. Comparatively, GW Pharmaceuticals has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500.

Institutional & Insider Ownership

47.6% of IGM Biosciences shares are held by institutional investors. Comparatively, 81.0% of GW Pharmaceuticals shares are held by institutional investors. 79.3% of IGM Biosciences shares are held by insiders. Comparatively, 3.1% of GW Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares IGM Biosciences and GW Pharmaceuticals' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares IGM Biosciences and GW Pharmaceuticals' top-line revenue, earnings per share and valuation.

GW Pharmaceuticals has higher revenue and earnings than IGM Biosciences. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

GW Pharmaceuticals beats IGM Biosciences on 7 of the 13 factors compared between the two stocks.

IGM Biosciences (NASDAQ:IGMS) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Analyst Recommendations

This is a summary of recent recommendations and price targets for IGM Biosciences and Ascendis Pharma A/S, as provided by MarketBeat.com.

IGM Biosciences currently has a consensus price target of $98.8750, indicating a potential upside of 44.36%. Ascendis Pharma A/S has a consensus price target of $187.6667, indicating a potential upside of 49.40%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts clearly believe Ascendis Pharma A/S is more favorable than IGM Biosciences.

Volatility & Risk

IGM Biosciences has a beta of -1.12, indicating that its stock price is 212% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.

Institutional & Insider Ownership

47.6% of IGM Biosciences shares are held by institutional investors. 79.3% of IGM Biosciences shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares IGM Biosciences and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares IGM Biosciences and Ascendis Pharma A/S's top-line revenue, earnings per share and valuation.

IGM Biosciences has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

IGM Biosciences beats Ascendis Pharma A/S on 7 of the 13 factors compared between the two stocks.

IGM Biosciences (NASDAQ:IGMS) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Volatility & Risk

IGM Biosciences has a beta of -1.12, indicating that its stock price is 212% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for IGM Biosciences and Arrowhead Pharmaceuticals, as provided by MarketBeat.com.

IGM Biosciences currently has a consensus price target of $98.8750, indicating a potential upside of 44.36%. Arrowhead Pharmaceuticals has a consensus price target of $85.3077, indicating a potential upside of 37.26%. Given IGM Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe IGM Biosciences is more favorable than Arrowhead Pharmaceuticals.

Institutional & Insider Ownership

47.6% of IGM Biosciences shares are held by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. 79.3% of IGM Biosciences shares are held by insiders. Comparatively, 4.0% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares IGM Biosciences and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares IGM Biosciences and Arrowhead Pharmaceuticals' top-line revenue, earnings per share and valuation.

IGM Biosciences has higher earnings, but lower revenue than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Arrowhead Pharmaceuticals beats IGM Biosciences on 7 of the 13 factors compared between the two stocks.

IGM Biosciences (NASDAQ:IGMS) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Risk and Volatility

IGM Biosciences has a beta of -1.12, indicating that its stock price is 212% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.28, indicating that its stock price is 128% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for IGM Biosciences and TG Therapeutics, as provided by MarketBeat.

IGM Biosciences presently has a consensus price target of $98.8750, indicating a potential upside of 44.36%. TG Therapeutics has a consensus price target of $64.00, indicating a potential upside of 42.89%. Given IGM Biosciences' higher probable upside, analysts clearly believe IGM Biosciences is more favorable than TG Therapeutics.

Institutional and Insider Ownership

47.6% of IGM Biosciences shares are held by institutional investors. Comparatively, 65.7% of TG Therapeutics shares are held by institutional investors. 79.3% of IGM Biosciences shares are held by insiders. Comparatively, 13.2% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares IGM Biosciences and TG Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares IGM Biosciences and TG Therapeutics' gross revenue, earnings per share and valuation.

IGM Biosciences has higher earnings, but lower revenue than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

IGM Biosciences beats TG Therapeutics on 7 of the 13 factors compared between the two stocks.